15
results
for author:"Seshagiri S."
in Literature Citations
| Bayesian modeling of the yeast SH3 domain interactome predicts spatiotemporal dynamics of endocytosis proteins. Tonikian R., Xin X., Toret C.P., Gfeller D., Landgraf C., Panni S., Paoluzi S., Castagnoli L., Currell B., Seshagiri S. et al. PLoS Biol. 7:e1000218-e1000218(2009) · Mapped (29) |
| Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. Jaiswal B.S., Janakiraman V., Kljavin N.M., Eastham-Anderson J., Cupp J.E., Liang Y., Davis D.P., Hoeflich K.P., Seshagiri S. PLoS ONE 4:e5717-e5717(2009) · Mapped (14) |
| Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Hoeflich K.P., Herter S., Tien J., Wong L., Berry L., Chan J., O'Brien C., Modrusan Z., Seshagiri S., Lackner M. et al. Cancer Res. 69:3042-3051(2009) · Mapped (3) |
| A specificity map for the PDZ domain family. Tonikian R., Zhang Y., Sazinsky S.L., Currell B., Yeh J.H., Reva B., Held H.A., Appleton B.A., Evangelista M., Wu Y. et al. PLoS Biol. 6:e239-e239(2008) · Mapped (47) |
| Regulation of ERK3/MAPK6 expression by BRAF. Hoeflich K.P., Eby M.T., Forrest W.F., Gray D.C., Tien J.Y., Stern H.M., Murray L.J., Davis D.P., Modrusan Z., Seshagiri S. Int. J. Oncol. 29:839-849(2006) · Mapped (6) |
| ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Dornan D., Shimizu H., Mah A., Dudhela T., Eby M., O'rourke K., Seshagiri S., Dixit V.M. Science 313:1122-1126(2006) · Mapped (14) |
| Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Hoeflich K.P., Gray D.C., Eby M.T., Tien J.Y., Wong L., Bower J., Gogineni A., Zha J., Cole M.J., Stern H.M. et al. Cancer Res. 66:999-1006(2006) · Mapped (3) |
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., Ince W.L., Janne P.A., Januario T., Johnson D.H. et al. J. Clin. Oncol. 23:5900-5909(2005) · Mapped (23) |
| De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., Wu P., Wiesmann C., Baker R., Boone D.L. et al. |
| Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Zhou H., Wertz I., O'Rourke K., Ultsch M., Seshagiri S., Eby M., Xiao W., Dixit V.M. |
| The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., Chen J., Chow B., Chui C., Crowley C. et al. Genome Res. 13:2265-2270(2003) · UniProtKB (1,019) |
| Identification of paracaspases and metacaspases. Two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Uren A.G., O'Rourke K., Aravind L., Pisabarro M.T., Seshagiri S., Koonin E.V., Dixit V.M. Mol. Cell 6:961-967(2000) · UniProtKB (5) |
| Baculovirus-based genetic screen for antiapoptotic genes identifies a novel IAP. Seshagiri S., Vucic D., Lee J., Dixit V.M. J. Biol. Chem. 274:36769-36773(1999) · UniProtKB (1) · Mapped (4) |
| Mutational analysis of Caenorhabditis elegans CED-4. Seshagiri S., Chang W.T., Miller L.K. FEBS Lett. 428:71-74(1998) · Mapped (3) |
| Caenorhabditis elegans CED-4 stimulates CED-3 processing and CED-3-induced apoptosis. Seshagiri S., Miller L.K. Curr. Biol. 7:455-460(1997) · Mapped (3) |
